The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
The Fund identifies and shares policy ideas and analysis to advance state health leadership, strong primary care, and sustainable health care costs.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is is a foundation that works to improve population health and health equity.
December 2004 (Volume 82)
Quarterly Article
Richard L. Kravitz
Naihua Duan
Joel Braslow
December 2024
Dec 19, 2024
Back to The Milbank Quarterly
Evidence-based medicine is the application of scientific evidence to clinical practice. This article discusses the difficulties of applying global evidence (“average effects” measured as population means) to local problems (individual patients or groups who might depart from the population average). It argues that the benefit or harm of most treatments in clinical trials can be misleading and fail to reveal the potentially complex mixture of substantial benefits for some, little benefit for many, and harm for a few. Heterogeneity of treatment effects reflects patient diversity in risk of disease, responsiveness to treatment, vulnerability to adverse effects, and utility for different outcomes. Recognizing these factors, researchers can design studies that better characterize who will benefit from medical treatments, and clinicians and policymakers can make better use of the results.
Author(s): Richard L. Kravitz; Naihua Duan; Joel Braslow
Keywords: evidence-based medicine; research design; population characteristics; genomics; statistics; United States Food and Drug Administration
Read on Wiley Online Library
Read on JSTOR
Volume 82, Issue 4 (pages 661–687) DOI: 10.1111/j.0887-378X.2004.00327.x Published in 2004